An Open-label, Randomized, 2-sequence, 2-period, 2-treatment, 2-part Study to Evaluate the Relative Bioavailability of SAR443820 in Tablet Formulation Versus Capsule Formulation in Fasted Condition (Part 1) and the Food-effect on SAR443820 in Tablet Formulation (Part 2) in Healthy Adult Male and Female Participants
Latest Information Update: 06 Apr 2023
At a glance
- Drugs Oditrasertib (Primary)
- Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
- Focus Pharmacokinetics
- Sponsors Sanofi
Most Recent Events
- 06 Apr 2023 New trial record